Target intelligence / Profile preview

Excitatory amino acid transporter 3 (EAAT3) (EAAT3)

Target
EAAT3
Molecular classification
Transporter — high-affinity glutamate transporter of the solute carrier family, Solute carrier (SLC) family — SLC1 family member, Neurotransmitter transporter — electrogenic amino acid symporter using ion gradients
01

Overview

Excitatory amino acid transporter 3 (EAAT3), encoded by SLC1A1, is a neuronal and epithelial high-affinity glutamate transporter expressed on dendrites and axon terminals that clears synaptic glutamate, transports aspartate, and uniquely among EAATs efficiently transports L-cysteine to support glutathione synthesis and protect against oxidative stress. It is a homotrimeric membrane transporter operating by an elevator mechanism that symports glutamate with three sodium ions and a proton and counter-transports potassium, with well-resolved cryo-EM structures detailing its outward-, intermediate-, and inward-facing conformations and ion/substrate coupling. Dysfunction or genetic variation in SLC1A1 is linked to dicarboxylic aminoaciduria, oxidative-stress–related neuronal loss, and associations with obsessive–compulsive disorder, and EAAT3 has emerging relevance in cancer biology.

Other names
Solute carrier family 1 member 1 (SLC1A1)EAAC1 (historical/neuronal EAAT3 designation in literature; inferred from SLC1A1/EAAT nomenclature; commonly used but not explicitly stated in retrieved pages — inference)
02

Mechanism of action

Substrate transporters/inhibitors would modulate glutamate/aspartate/cysteine uptake by altering the coupled symport cycle that moves glutamate with 3 Na+ and 1 H+ and exchanges 1 K+ via an elevator mechanism. Substrate-specific interactions: EAAT3 uniquely transports L-cysteine efficiently, recognizing it in thiolate form via key binding-site residues (D444, R447, N451); molecules affecting these interactions can change uptake and redox homeostasis.

03

Biological functions

Glutamate uptake to terminate synaptic signaling and maintain low extracellular glutamateAspartate transportMajor neuronal cysteine uptake for glutathione synthesis and protection from oxidative stressCoupled symport of glutamate with 3 Na+ and 1 H+, and counter-transport of K+ (elevator mechanism)Supports GABAergic neurons by supplying glutamate precursor for GABA synthesis
04

Disease associations

Neurodegenerative disease/oxidative stress phenotypes: EAAT3 loss reduces neuronal glutathione, increases oxidative stress, and leads to age-dependent neuronal loss (notably substantia nigra) in miceNeuropsychiatric disease: association of SLC1A1 polymorphisms with obsessive–compulsive disorder (meta-analysis)Inborn error of metabolism: mutations cause dicarboxylic aminoaciduria (glutamate–aspartate transport defect)Cancer: EAAT3 activity/activation reported in cancers; structural work notes dysfunction linked to neurological pathologies and activation in cancers
05

Safety considerations

Excessive inhibition of EAAT3 may elevate extracellular glutamate, risking excitotoxicityReducing EAAT3-mediated cysteine uptake may deplete neuronal glutathione, increasing oxidative stress and neuronal vulnerabilityBroad modulation of EAAT transporters can affect ion homeostasis due to coupled Na+/H+ symport and K+ antiport, with potential electrophysiological consequences
06

Interacting drugs

No approved selective EAAT3 drugs identified in retrieved sources; EAAT3 is considered a potential pharmacologic target with compounds and experimental treatments that modulate expression/trafficking/function reported in the literature review (general modulators, not named approved drugs)

1 more in the full profile.

07

Biomarkers

SLC1A1 genetic variants associated with OCD risk (potential stratification marker in neuropsychiatric research)Neuronal glutathione levels and oxidative stress markers may reflect EAAT3-mediated cysteine uptake activity (biological inference supported by knockout phenotypes)Dicarboxylic aminoaciduria due to SLC1A1 mutations could serve as a diagnostic biomarker for transporter dysfunction

Beyond the preview

Go deeper on Excitatory amino acid transporter 3 (EAAT3) (EAAT3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Excitatory amino acid transporter 3 (EAAT3) (EAAT3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call